NAS10026,816−5.70%S&P7,430−3.37%GOLD$4,105+0.80%BTC$75,995−5.48%VIX25.68+54.61%latest tape · as of 16:02 UTC
The Screen · Healthcare · Drug Manufacturers - General
AbbVie
ABBV · a US exchange · USD · Market cap $513.9B · 57,000 employees
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
FAIL · Does not pass the screen
294.83 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 16:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price294.83 USD at the 4 Nov 2026 close
Our value readFair vs our fair value, as of 4 Nov 2026
Positioning political selling, disclosed 2026-09-14
Options put/call open interest 0.39, read 2026-11-02
Ethical does not pass the values gate
Price294.83 USD
Fair value322.22
Ethical score10.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-02Read Accumulation264.34+11.5% to today ✓Distribution gives way to Accumulation
2026-08-29Read Distribution261.83+12.6% to today Markup gives way to Distribution after a 15% rise in 8 weeks
2026-07-02Read Markup227.23+29.7% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
AbbVie holds its Accumulation at $294.83. The statistical read favours the buyers, held for 19 days.
As held on the ledger · 2026-11-04
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 19 days
Price at the screen
$294.83
Valuation
82.14 trailing · 17.95 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.23
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
50.39%
Below 33%
Interest-bearing debt is 50.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.20%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
13.30%
Below 49%
Money owed to the company is 13.3% of assets, under the 49% limit.
Pass
Revenue purity
0.43%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
AbbVie's business is in a permissible area, but its interest-bearing debt is about 50% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ABBV's ethical verdict changes
Today ABBV does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades at roughly a 9% discount to our $322.22 fair value, 10.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 8.5% discount to the base estimate.
Where our models see it going: fair-value estimate $322.22, with a range of $267.33 to $445.54, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Pharmaceuticals Giant with a Shadow of Debt
Imagine every time a new drug is prescribed, a pharmaceutical giant collects a small fee for its innovation, and that's AbbVie. The company's portfolio includes treatments for autoimmune and inflammatory diseases, with products like Skyrizi and Rinvoq leading the charge. But when we delve into its financials, something sticks out - a substantial debt load that trips our ethical screen. This is why we're avoiding it.
AbbVie's revenue growth of 10% and profit margin of 10% sound promising, and a forward P/E of 16.1x might suggest a bargain in a sector known for high multiples. Yet, the market consensus rating of 'buy' with a median target of $280 per share doesn't account for the elephant in the room - a debt ratio that our ethical screen flags as problematic. This risk overshadows the potential gains, making AbbVie a company to avoid.
Risk sits heavily here, predominantly due to AbbVie's debt ratio, which fails our ethical screen. This is a crucial metric, as high debt can constrain a company's ability to invest in future growth and weather economic storms. While the numbers on the surface might paint a different picture, our ethical-first approach compels us to sidestep the risk. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ABBV trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-30Accumulation$290.79+1.5%Entry 24
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$286.39+1.1%Entry 23
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$283.40+0.0%Entry 22
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$283.40+0.0%Entry 21
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$283.40+0.0%Entry 20
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$283.40+0.0%Entry 19
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$283.40+0.0%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$283.40+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$283.40+7.2%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253.
2026-10-11Accumulation$264.34+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (29 analysts) rates it buy, with a mean price target of $253.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
